This study is not yet accepting patients

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

a study on Malignant Neoplasm

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Hala Borno

Description

Summary

This trial studies how well a follow-up phone call regarding financial reimbursement program (FRP) works in improving cancer patients' access to therapeutic cancer clinical trials. Follow-up phone call intervention regarding FRP may improve recruitment of cancer patients to cancer therapeutic clinical trials.

Official Title

A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): A Financial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

Details

There are limited financial models that address the economic hardship associated with clinical research participation and how it might restrict clinical research access. The Lazarex Foundation offers a financial reimbursement program (FRP) to help patients and caregivers cover the out-of-pocket costs associated with clinical trial participation for almost ten years.

iMPACT is a pilot study to assess the overall feasibility of conducting a multi-center trial of the Lazarex sliding scale FRP among sociodemographically diverse adult patients of all cancer types enrolling/potentially enrolling in therapeutic clinical trials (TCTs). The study will formalize informing patients about the Lazarex sliding-scale FRP in order to evaluate whether operationalizing intensive follow-up about the Lazarex FRP improves recruitment to cancer TCTs.

All patients will be offered information about the FRP at initial time of TCT discussion/consent for the iMPACT study, however, participants will be randomized 1:1 to receive an additional follow-up call about the FRP or no follow-up call (usual care). Participants who are randomized to usual care will be provided a phone number for the Lazarex Foundation that they may contact directly. Therefore all patients in the study have access to FRP eligibility assessment through the Lazarex Foundation.

Participants will be surveyed at baseline (time of consent to iMPACT) and interviewed 30 days after consent to iMPACT. If a participant enrolls in a therapeutic clinical trial, he/she will also be given an additional survey after TCT participation and interviewed up to 90 days after TCT participation.

Keywords

Malignant Neoplasm Neoplasms Cancer Educational Materials Follow-Up Care

Eligibility

You can join if…

Open to people ages 18 years and up

  • Eligible patients to be randomized for the iMPACT study must:
  • Carry a diagnosis of cancer
  • Patient is considered potentially eligible for a cancer therapeutic clinical trial (TCT) and is being offered an opportunity to sign an informed consent document for the cancer TCT
  • Eligible patients to receive FRP (these documents will be requested by Lazarex

Foundation, however research coordinator at site can help patient collect documents):

  • Have a household income =< 700% of the 2018 Health and Human Services (HHS) Poverty Guidelines
  • Willing to provide proof of household income. Acceptable proof of income documents are: first two pages of signed copy of income tax return, or if a return is not filed, a copy of the most recent pay stub, unemployment check, Supplemental Security Income (SSI), Social Security Disability (SSD), or public assistance benefit notification. If a patient is not employed, they must submit a signed letter stating their current financial situation

You CAN'T join if...

  • Currently enrolled on clinical trial

Locations

  • University of California, San Francisco not yet accepting patients
    San Francisco California 94143 United States
  • USC / Norris Comprehensive Cancer Center not yet accepting patients
    Los Angeles California 90033 United States

Lead Scientist

  • Hala Borno
    Dr. Hala Borno is a medical oncologist specializing in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. She cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF).

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03943082
Study Type
Interventional
Last Updated